Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan in pediatric hypertension
NCT00171041Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2002
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of valsartan in hypertension (HTN) (4 arms), sponsored by Novartis. Primary endpoint: Change from baseline in sitting systolic blood pressure at 2 weeks. Started Dec 2002; status: completed.
02
Drugs
valsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00171041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171041.